BFC Planning’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$788K Buy
4,881
+60
+1% +$10K 0.03% 464
2026
Q2
$914K Buy
4,821
+83
+2% +$15.6K 0.04% 427
2026
Q1
$934K Buy
4,738
+3,309
+232% +$638K 0.04% 374
2025
Q4
$263K Buy
1,429
+132
+10% +$23.2K 0.01% 764
2025
Q3
$199K Buy
+1,297
New +$196K 0.01% 665
2025
Q2
– Sell
-841
Closed -$123K – 2678
2025
Q1
$123K Buy
841
+1
+0.1% +$145 0.01% 785
2024
Q4
$110K Sell
840
-173
-17% -$24.2K 0.01% 819
2024
Q3
$158K Buy
+1,013
New +$164K 0.01% 695

Other funds holding AZN

BFC Planning's AZN Position: Q3 2026 in Review

BFC Planning increased its AstraZeneca (AZN) stake by 1.2% in Q3 2026, buying an estimated $10K and bringing the position to 4,881 shares worth $788K. The position accounts for 0.03% of the portfolio, ranked #464.

BFC Planning first reported a position in AZN in Q3 2024 and has held it in 8 quarters since. The position peaked at $934K in Q1 2026. 1,222 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • BFC Planning held 4,881 shares of AstraZeneca worth $788K as of Q3 2026.
  • BFC Planning bought 60 AstraZeneca shares in Q3 2026, an estimated $10K.
  • AstraZeneca made up 0.03% of BFC Planning's portfolio in Q3 2026, its #464 holding.
  • BFC Planning first reported a position in AstraZeneca in Q3 2024 and has held it in 8 quarters since.
  • BFC Planning's AstraZeneca position peaked at $934K in Q1 2026.
  • 1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.